Keynote lecture

Welcome and Opening of the Biotech Atelier

Advanced therapy medicinal products (ATMPs)

Digital Health and Artificial Intelligence

Real-World Evidence (RWE) and HTA

Interview

Personalized Medicine: Recent Developments

Personalized Medicine: Biomarkers

Human Capital in “Corona Times” and beyond

The Life Science Funding in “Corona Times” and beyond

Digital Therapeutics

Biotechnology Innovation and Investment – Before, Now and Then

Innovations in the COVID-19 Era

Artificial Intelligence in the COVID-19 Era

Personalized Medicine: Biobanking and Population Genetics

Chief Patient Officer

Future of clinical trials, AI and data

Personalization, Pharmacogenetics and Pharmacogenomics

Innovation in Medicine – ATMPs

Clinical Trials

How Germany managed the coronavirus crisis

Personalized Psychiatry

Regulatory Challenges in the COVID Era

Medical Cannabis – the Wonder Substance

Hospital Exemption for ATMPs

Medical Devices in the Digital Health Era

COVID-19: the New Reality in Bulgaria and Worldwide

COVID-19 Diagnostic and Therapy, the Bulgarian Perspective

COVID-19 Diagnostics: Hear the Experts

Water and Biotechnologies

Plant Biotechnology: Beyond

Keynote

Fireside chat

Office hours

Keynote

Jury QnA and Awards

Keynotes – COVID-19

Healthcare and Pharma Dynamics, 2020

Precision Medicine’s Potential and Current Gaps

11 years ATMPs

ATMPs, patient’s perspective

ATMPs, logistics

ATMPs, Leveraging the Digital Supply Chain

IBM Solutions in Healthcare

The Supercomputers – modern accelerators of innovation in healthcare

Beyond healthcare system towards a health-tech ecosystem

3D Bioprinting? (CTI Biotech)

Big Data and AI in Digital Health

BDADH – GATE Institute – Research areas and application themes

BDADH – Session 2 opening

BDADH – Session 1 opening

BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function

BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health

BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer

BDADH – Q & A Session 1

BDADH – Session 2 opening

BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation

BDADH – Digital twin modelling of patients with cognitive disorders

BDADH – Q & A Session 2

Healthtech and Biotech startup track

PBB – The future of plant agriculture

PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding?

FCTAID – Welcome and opening

FCTAID – Setting the scene: Future of clinical trials – what it would be?

FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO!

FCTAID – Clinical Trials market & Financial impact – Global overview

FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee.

FCTAID – Discussion

FCTAID – Break 1

FCTAID – The lack of data as an obstacle to the clinical trials development in CEE

FCTAID – Patient-centric software powering decentralised trials

FCTAID – Research transparency, public involvement and proportionality of ethical review

FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria

FCTAID – Decentralised clinical trials: moving from nicety to necessity

FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care

FCTAID – Q&A

FCTAID – Break 2

FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS

FCTAID – How to embed research in a national health service

FCTAID – Clinical Trials in Bulgaria – Key Challenges

FCTAID – Sleep disorders and clinical trials: new challenges and perspectives

FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials

FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision

FCTAID – The importance of clinical research in saving patient’s life – academy point of view

FCTAID – Break 3

FCTAID – Improved adverse event/medical error reporting

FCTAID – Discussion 2

FCTAID – Conclusions and closure

FCTAID – Using AI to generate Real World Evidence (RWE)

PPP – Welcome and Opening

PPP – Personalized Medicine – the New Reality in Medical School?

PPP – Moving from disease treatment to disease prevention – personalization is the key

PPP – Implementation of Pharmacogenetic testing: what are the priorities?

PPP – Pharmacogenetics in oncology clinical practice

PPP – Break 1

PPP – Progressing a data driven healthcare system

PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition

PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform

PPP – Rational Cancer Therapy

PPP – Closing discussion and remarks

ATMPs – Opening

ATMPs – Introduction

ATMPs – EU ATMP development landscape and outlook

ATMPs – ATMP update and Regulatory Strategy

ATMPs – Q&A session

ATMPs – Break 1

ATMPs – Nonclinical Challenges and Cases with ATMPs

ATMPs – CMC Challenges and case studies with ATMPs

ATMPs – Q&A session 2

ATMPs – Break 2

ATMPs – The ATMP post approval path – patient and market access

ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective

ATMPs – Q&A session 3

Featured Posters 1D

Featured Posters 3D

Featured Posters 4D

FCTAID – Patient First: changing the clinical trials paradigm

IRI – Research infrastructures: Why do we need them?

IRI – Covid – what can infrastructures do going forward

IRI – Infrastructures Role in developing Personalized Health

Potable water and biotechnologies

Topic for the near future: Water microbiome

Wastewater and Biotechnologies

The future of the water sector: Matching needs and technologies